The FDA has approved an oral version of Novo Nordisk’s Wegovy for weight loss and cardiovascular risk reduction. Clinical trials showed the pill achieves similar efficacy to the injectable form, with patients losing approximately 14% of their body weight. This approval marks the first time a GLP-1 pill has been cleared for obesity, potentially increasing access for those averse to injections.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.